New trial (S1802) for treatment of men with newly diagnosed, metastatic prostate cancer

Earlier this month we had mentioned hearing about a new trial to explore whether local ablation of the primary tumor could improve the outcomes of men initially diagnosed with metastatic prostate cancer. … READ MORE …

Does local treatment at time of diagnosis improve outcomes for men initially diagnosed with metastatic disease?

Over the years, a good deal of data has been accumulated suggesting that local treatment (ablation) of the primary tumor may have benefit in the long-term outcomes of men with metastatic prostate cancer at time of initial diagnosis. … READ MORE …

The potential for use of enzalutamide in HSPC: an update

We note that Pfizer and Astellas have recently modified the protocols for two large, international, randomized, Phase III clinical trials to see if they can get earlier results that might affect the potential for use of enzalutamide (Xtandi) in some groups of men with hormone-sensitive prostate cancer (HSPC). … READ MORE …

When is a metastasis really metastatic today?

There is an interesting editorial commentary by Dr. Daniel George that was published just over a week ago on the UroToday web site. … READ MORE …

A rare case of cutaneous, metastatic prostate cancer

Last week we learned of a distinctly unusual case of advanced prostate cancer, and the patient has given us his permission to provide our readers with some specific information about his case. … READ MORE …

Prediction of potentially lethal forms of prostate cancer

An international, multi-institutional group of researchers appears to have been able to validate a new way to predict risk for aggressive forms of localized prostate cancer that have a high probability for progression to metastatic disease and prostate cancer-specific mortality. … READ MORE …

FDA approves new form of abiraterone acetate for treatment of prostate cancer

On May 23, the US Food and Drug Administration apparently approved a new formulation of abiraterone acetate, known as Yonsa®, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …